CAR-T Meeting 2022 | Challenges of CAR-T therapy in the real-world setting
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, outlines some of the obstacles in moving chimeric antigen receptor T-cell (CAR-T) therapies from clinical trials to the real-world. Over the past few years, CAR-T therapies have undoubtedly changed the treatment landscape for patients with hematological malignancies. Nevertheless, it is essential to investigate whether results from clinical trials match data from the real-world setting, and navigate through the large amounts of data on CAR-T. In addition, it is important to improve access to CAR-T therapies and scale up manufacturing. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion
Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi
Speaker’s Bureau: Takeda
Research support: Takeda, BMS/Celgene
